2013 - 2016 Towards personalized treatment of gliomas -specifically to explore the indication of neoadjuvant chemotherapy for gliomas-
2010 - 2012 Towards molecular-guided personalized therapy of gliomas -clarifyingthe indication of neoadjuvant approach for gliomas-
2008 - 2010 Chemosensitization of human glioma cellt to chemotherapeutic agent temozolomide
2007 - 2008 神経膠腫における分子遺伝学的分類法の構築と、個別化治療の確立
1997 - 2000 Molecular analysis of key factors involved in the mechanism of invasion in gliomas
1996 - 1998 Gene therapy for malignant brain tumors via TIMPs-expressing replication-competent viruse
1996 - 1998 Neurotrophic Effects of Cytokine-activated Astrocytes.-Basic research for Elucidation of Interaction between Neuron and Glia, and Restoration of Damaged Neuronal Function-
1996 - 1996 ヒト神経膠腫の悪性化因子に関する研究
1993 - 1995 NEUROTROPHIC ACTIVITY OF CYTOKINE-ACTIVATED ASTROCYTES
Show all
Papers (140):
Hikaru Sasaki, Yohei Kitamura, Masahiro Toda, Yuichi Hirose, Kazunari Yoshida. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy. Brain tumor pathology. 2024
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranari, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. Journal of Neuro-Oncology. 2024. 166. 3. 557-567
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, et al. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. Brain Tumor Pathology. 2023
Hikaru Sasaki, Tokunori Kanazawa, Yohei Kitamura, Masato Nakaya, Hirokazu Fujiwara, Tokuhiro Kimura, Shunsuke Nakae, Shigeo Ohba, Yuya Nishiyama, Masahiro Toda, et al. LW-8 TREATMENT STRATEGY FOR OLIGODENDROGLIOMAS WITH NEOADJUVANT STRATEGY AND STAGED RESECTION UTILIZING THEIR CHEMOTHERAPEUTIC RESPONSIVENESS. Neuro-Oncology Advances. 2022. 4. Supplement_3. iii27-iii27
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Tohmoto K, K, Kuranari Y, Imai R, Yamamoto Y, et al. A prospective multicenter phase I/IIa study of prospective neoadjuvant bevacizumab for newly diagnosed glioblastoma. Neuro-Oncology Advances. 2022. 4. 3. iii7
初発膠芽腫に対するベバシズマブ術前療法探索的第 II 相他施設共同臨床試験-第2報
(第41回日本脳腫瘍学会 2023)
乏突起膠腫に対する術前化学療法を応用した段階的切除戦略
(第41回日本脳腫瘍学会 2023)
CTNI-45 - Upfront chemotherapy and subsequent resection utilizing neoadjuvant strategy for oligodendrogliomas
(The 28th Annual Meeting of the Society for Neuro-Oncology (SNO) 2023)
日本頭蓋底外科学会
, 日本脳腫瘍の外科学会
, Society for Neuro-Oncology (SNO)
, 日本分子脳神経外科学会
, JCOG(日本臨床腫瘍研究グループ)脳腫瘍グループ
, 日本癌学会
, 日本臨床腫瘍学会
, 日本癌治療学会
, 日本脳腫瘍病理学会
, American Association for Cancer Research (AACR, active membership)
, 日本脳神経外科コングレス
, 日本脳腫瘍学会
, 日本脳神経外科学会